Osteocal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Osteocal

Quick Facts

Classification Key Active Ingredient Primary Use
Hormone/Anti-resorptive Agent Calcitonin (typically salmon calcitonin) Osteoporosis, Paget's Disease

What is Osteocal?

Osteocal is a brand name often associated with a medication containing calcitonin, a polypeptide hormone that plays a role in calcium regulation and bone metabolism. It is most commonly administered as an injection or a nasal spray formulation. The active ingredient, calcitonin (often a synthetic form derived from salmon, which has greater potency than the human equivalent), is classified as an anti-resorptive agent.

The primary therapeutic function of calcitonin is to reduce the level of calcium in the blood by acting directly on the bone. The hormone works by inhibiting the activity of osteoclasts—the cells responsible for breaking down bone tissue, a process known as bone resorption. By slowing this breakdown, calcitonin helps to prevent the release of calcium from the bone matrix into the bloodstream.

Clinically, the medication is used for specific indications, including the treatment of postmenopausal osteoporosis, the management of Paget's disease of the bone, and the treatment of elevated blood calcium levels (hypercalcemia). In the context of postmenopausal osteoporosis, calcitonin may be prescribed to increase bone mineral density and potentially reduce the risk of vertebral fractures. Its use for other indications has become more limited with the introduction of newer drug therapies.

What side effects are possible with Osteocal?

Possible Side Effects and Safety Information

The safety profile of the active ingredient, calcitonin (salmon), is classified by regulatory authorities based on the frequency and the physiological system affected. This section presents officially documented adverse reactions and high-level safety considerations.

Regulatory Classification of Adverse Reactions

The most commonly reported side effects are grouped into frequency categories, ranging from Very Common to Rare. Very Common reactions (occurring in ge 1/10 of patients) typically include nausea (with or without vomiting), flushing of the face or upper body, and for the injectable form, injection site reactions (such as pain or inflammation). Effects classified as Common (ge 1/100 to < 1/10) include gastrointestinal disturbances like diarrhea or abdominal pain, and neurological effects such as headache or dizziness.

Serious Safety Considerations and Constraints

The regulatory label documents certain serious adverse reactions. These include the potential for severe hypersensitivity reactions, such as anaphylactic shock. Furthermore, a meta-analysis of clinical trials has noted an association between the long-term use of calcitonin-salmon and an increased risk of malignancies (cancer), a safety concern explicitly documented by regulatory bodies.

Treatment is formally contraindicated in patients with a known hypersensitivity to the drug or in those with pre-existing hypocalcemia (low blood calcium levels). Safety documents also note that certain adverse effects, such as nausea and a transient decrease in calcemia, are often more frequent upon the initiation of therapy and may lessen with continued use. For the pediatric population, the safety and efficacy of the medication have not been established.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented overdose profile for Osteocal (a Calcium and Vitamin D3 combination) centers on the development of hypercalcaemia and hypervitaminosis D. Symptoms listed in regulatory labeling include anorexia, nausea, vomiting, thirst, polyuria (increased urination), muscle weakness, and mental disturbances.


Required Emergency Actions

Classification Official Regulatory Statement
Immediate Action Treatment with the medication must be immediately discontinued.
Antidote Status No specific antidote is known or documented in official labeling.
Management Treatment is generally symptomatic and supportive, often requiring close monitoring of serum calcium levels and renal function (serum creatinine).
Severe Outcomes Extreme hypercalcaemia may lead to cardiac arrhythmias, irreversible renal damage, coma, and death.

When Urgent Medical Help is Required

Urgent medical attention must be sought immediately if symptoms indicative of severe hypercalcaemia occur. This includes signs of cardiac irregularity, profound mental disturbances, or any progression toward collapse. Regulatory documents also note that overdose must be strictly avoided during pregnancy due to the documented risk of physical and mental impairment in the child.

Therapeutic Uses of Osteocal

Osteocal, which contains calcium and Vitamin D, is commonly used to help with symptoms related to systemic imbalance or physical discomfort linked to deficiencies of these essential nutrients.

This combination is considered relevant for easing issues associated with systemic imbalance related to calcium and vitamin D, which is applied across domains where additional symptomatic support is needed. The therapeutic focus is applied in addressing situations involving certain distressing symptoms, relevant when supportive symptom management is appropriate for conditions characterized by periods of heightened symptoms, such as those associated with the symptoms of increased neurological or muscular activity. This formulation may assist with supportive symptom management, relevant in contexts involving heightened systemic burden.

This helps address symptoms related to physical discomfort and inflammatory or irritative states. It contributes to easing the overall symptom burden, assists with maintaining functional stability, and supports patients during episodes of heightened discomfort.

“Symptomatic relief helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Support for Symptoms that Interfere with Daily Functioning
This combination is commonly used to help with symptoms that interfere with daily functioning in contexts where short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

Who Can and Cannot Use Osteocal?

This section outlines the official population eligibility and non-eligibility rules for Osteocal (a Calcium/Vitamin D combination), strictly based on governmental regulatory documents.


Eligibility Scope

Classification Official Regulatory Statement
Populations for whom use is allowed Adults and older adults established as having calcium and vitamin D deficiency or needing supplementation for osteoporosis treatment.
Populations for whom use is not recommended Infants and children under 12 years of age for the standard adult dosage form.
Populations for whom use is contraindicated Patients with severe renal impairment, hypercalcaemia, hypervitaminosis D, nephrolithiasis (kidney stones), hypercalciuria, or known hypersensitivity to the ingredients.
Age-related eligibility rules Use in children under 12 years is not generally recommended; use in adults and older adults is established.
Pregnancy and lactation eligibility Permitted during both pregnancy and lactation, provided specific regulatory maximum daily intake levels are not exceeded.

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility primarily based on the patient's metabolic capacity to manage supplemental calcium and vitamin D. Contraindications are required for populations whose current health status, such as pre-existing hypercalcaemia or severe renal impairment, would be compromised by the medication. Restricted use with caution and monitoring is advised for patients with mild to moderate renal impairment or conditions like sarcoidosis, where the risk of metabolic imbalance is heightened.

What should I know about interactions with other medicines?

The official regulatory profile for Osteocal (a Calcium and Vitamin D combination) is defined by pharmacokinetic interference and pharmacodynamic risks, strictly based on government documentation. Interactions primarily involve the calcium component reducing the systemic exposure of co-administered medicines through chelation.

Official Interaction Classifications

Interacting Substance Categories Mechanistic Basis Cited in Labels
Antibiotics (Tetracyclines, Quinolones) Chelation (Reduced Absorption)
Bisphosphonates, Levothyroxine Interference with Absorption
Cardiac Glycosides, Thiazide Diuretics Additive Pharmacodynamic Effect
Strong CYP3A4 Inducers (Anticonvulsants) Increased Catabolism of Vitamin D

Mandatory Administration Requirements

To prevent a reduction in the plasma concentration of co-administered drugs, regulatory documentation requires a mandatory separation of dose timing for certain medicines. This rule specifically applies to Bisphosphonates, Tetracycline and Quinolone antibiotics, and Levothyroxine.

Official Interaction Statements

  • Co-administration with Thiazide Diuretics increases the risk of hypercalcemia, a risk heightened in elderly patients and individuals with compromised renal function.
  • The use of Cardiac Glycosides concurrently with Osteocal may increase the potential for cardiac arrhythmias due to additive effects on serum calcium concentration.
  • Certain foods containing oxalic or phytic acid (e.g., spinach, whole grains) are documented to decrease the intestinal absorption of calcium.

The official interaction profile structures the requirements for co-administration around avoiding the chelation of key medicines and managing the risk of additive hypercalcemic effects across sensitive patient populations.

Mechanism of Action

The action of Osteocal is defined by a dual-mechanism profile that affects two primary biological systems: the regulation of bone tissue turnover and the modulation of pain signaling.

Inhibiting Osteoclast Activity and Bone Resorption

This core mechanistic domain is initiated by the active ingredient acting as a high-affinity agonist at the Calcitonin Receptor (CTR) on osteoclasts—the cells responsible for bone breakdown. Receptor activation triggers an immediate intracellular cascade that rapidly shuts down the cell’s resorptive function. This action produces a physiological suppression of bone tissue breakdown and reduces the acute efflux of calcium and phosphate from the bone matrix into the bloodstream. This effect contributes to the compound's pharmacodynamic profile by decreasing the breakdown of bone tissue.

Modulating Nociceptive Signaling and Mechanism Limitations

A separate mechanistic domain involves the modulation of neuronal excitability and nociceptive signaling pathways in the nervous system, hypothesized to include interaction with ion channels and neurotransmitter systems. This effect contributes to the compound's pharmacodynamic profile by modulating pain transmission independent of its bone effect. A key limitation to the anti-resorptive mechanism is receptor tachyphylaxis, where chronic exposure leads to the downregulation of the CTR on osteoclasts, causing the bone effect to diminish over time.

Dosage and Administration Information

Osteocal is administered through the oral route, typically supplied in a chewable tablet form. The official dosing regimen varies based on the context of use, whether it is for the treatment of calcium and Vitamin D deficiency or as an adjunct to specific osteoporosis therapy.

For adult and elderly patients, the standard daily dose usually aligns with regimens of one tablet twice daily for certain formulations or one to three times daily for others, depending on the required total intake of elemental calcium and Vitamin D3. This schedule establishes a daily frequency pattern intended for sustained therapeutic use.

The proper administration of the tablet depends on the specific formulation; chewable forms are explicitly meant to be chewed or sucked and not swallowed whole. Furthermore, the official protocol includes special procedural conditions involving time separation from other drugs. To prevent the impairment of absorption, a minimum interval of time, which can range from one to four hours, is required between the intake of Osteocal and certain medications, such as bisphosphonates or levothyroxine.

Regarding use in specific populations, the prescribing information states that while no dose adjustment is required for patients with hepatic impairment, the medicine is contraindicated in severe renal impairment. Use in the paediatric population is generally not recommended unless specifically indicated for deficiency. If a dose is missed, standard instructions are to take the dose as soon as remembered, unless it is near the time for the next scheduled dose, in which case the missed dose must be skipped.

Recent Clinical Evidence

Osteocal: Recent Clinical Evidence

Laboratory Studies

Osteocal's activity was the subject of numerous in vitro and animal studies. These laboratory studies have explored the compound's behavior, focusing on specific receptor subtypes. Studies examined the compound's potential interaction with Receptor A. Some findings suggested an agonistic effect, but the clinical relevance of this finding is currently unclear. Inhibition studies assessed the compound's effect on Enzyme B activity. Findings were mixed regarding the consistency of this inhibitory action across different cell lines.


Clinical Efficacy Research

Clinical trials investigated whether the compound influenced overall pain scores and sleep quality in patients with chronic neuropathic pain. Most phase 2 and 3 studies were randomized, placebo-controlled trials of 8-12 weeks' duration.

  • Neuropathic Pain Scores: Primary outcome assessments focused on changes in the Brief Pain Inventory (BPI) scores. The research examined the potential for a sustained observation of the effect on symptoms across the trial period. Comparative trials evaluating the compound against existing standard treatments are limited.
  • Sleep Quality: Secondary endpoints included self-reported sleep quality measures, such as the Pittsburgh Sleep Quality Index (PSQI). Analysis focused on comparing patient-reported scores in the compound group versus the placebo group.

Safety and Tolerability Profiles

Safety studies evaluated tolerability across general populations, noting the occurrence of adverse events such as dizziness and somnolence. These studies examined the frequency and severity of side effects across treatment groups.

Research indicated that clearance of the compound may be altered in people with pre-existing kidney conditions. Evidence regarding the effects of administration for periods exceeding one year remains limited. Current research is focused on gathering data on potential long-term safety signals.

Key Studies & References

  1. Study Details | NCT01496365 | Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | ClinicalTrials.gov
  2. Osteocalcin, Vascular Calcification, and Atherosclerosis: A Systematic Review and Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Osteocal (FAQ)

Q: Are headaches a known side effect of Osteocal?

A: Official regulatory safety documents for the active ingredient indicate that headache is classified as a Common side effect, meaning it may occur in at least 1 out of 100 patients. This information is part of the overall safety profile reported in clinical studies.


Q: Does Osteocal interact with common over-the-counter pain relievers?

A: Regulatory information specifically warns about interactions with certain prescription drugs, such as Tetracycline and Quinolone antibiotics, Bisphosphonates, and Levothyroxine. General over-the-counter pain relievers are not explicitly listed, but the official protocol emphasizes the need to separate this medicine from many co-administered substances to ensure proper absorption.


Q: What is the recommended age range for people taking Osteocal?

A: Official prescribing information states that the use of Osteocal is established for adults and older adults who require supplementation. The medicine is not generally recommended for the pediatric population (children under 12 years of age).


Q: Can pregnant or breastfeeding women take Osteocal?

A: According to the official product information, taking Osteocal is generally permitted during both pregnancy and lactation. Use is generally permitted, provided that regulatory maximum daily intake levels are not exceeded.


Q: What happens in the body when Osteocal starts working?

A: The medicine begins its work by affecting the cells responsible for bone turnover. Its mechanism is to inhibit the activity of osteoclasts, which are the cells that break down bone tissue. By slowing this process, it reduces the release of calcium from the bone into the bloodstream.


Q: Is it okay to take other vitamin supplements while on Osteocal?

A: Since Osteocal contains Vitamin D, regulatory documents state that the medicine is contraindicated (should not be used) in patients with hypervitaminosis D (excessive levels of Vitamin D). Regulatory warnings advise against concurrent use of other supplements that could lead to an excessive total intake of this vitamin.


Q: What should I avoid eating or drinking while taking Osteocal?

A: Official interaction statements advise against co-administration with foods containing oxalic or phytic acid—found in things like spinach and whole grains—as these substances can decrease the intestinal absorption of the calcium component.


Q: Can taking too much Osteocal cause a problem?

A: Excessive intake can potentially lead to conditions such as hypercalcaemia (high blood calcium) or hypervitaminosis D (high vitamin D levels). These conditions are contraindications for its use and are associated with specific safety risks.


Q: Does taking Osteocal require any special dietary changes?

A: The official documentation requires specific timing rules for taking the medicine to avoid interference with the absorption of other medicines or certain foods. This procedure is required to manage the interaction with substances like oxalic or phytic acid in foods.


Q: Is it true that Osteocal helps with joint pain as well?

A: The medicine’s mechanism of action does include a domain that involves modulating pain transmission in the nervous system. This effect is separate from its primary bone-related effect, and its effectiveness regarding specific 'joint pain' is not explicitly confirmed by regulatory bodies.


Q: Why do some people take Osteocal for reasons other than osteoporosis?

A: Official regulatory documents define the indications for Osteocal. The medicine is officially approved for the treatment of calcium and Vitamin D deficiency in addition to its use as an adjunct to specific osteoporosis therapy.


Q: Do I need to take Osteocal at a specific time of day?

A: While an exact time of day is not usually mandatory for the dose itself, the official protocol includes special procedural conditions requiring separation of the dose timing from the intake of certain other medications to prevent absorption issues.


Q: Can Osteocal affect my sleep patterns?

A: The safety studies for the medicine evaluated general tolerability and noted adverse events such as dizziness and somnolence (drowsiness). Clinical research has also investigated its effect on sleep quality as a secondary endpoint.


Q: Can Osteocal interact with thyroid medications?

A: Yes, the official interaction profile explicitly mentions that Levothyroxine (a common thyroid medication) is one of the drugs that requires a mandatory separation of dose timing from Osteocal to prevent the medicine from reducing its absorption.


Q: What are the most common but mild side effects of Osteocal?

A: The most common reactions (ge 1/10) reported in studies include nausea, flushing of the face or upper body, and injection site reactions (for non-oral formulations). Common reactions (ge 1/100) include gastrointestinal upset, headache, and dizziness.


Q: Is it normal to feel a little nauseous when first starting Osteocal?

A: Yes, regulatory safety documents note that certain adverse effects, such as nausea, are often more frequent upon the initiation of therapy. For many patients, these effects may lessen or resolve with continued use of the medicine.


Q: Why is proper absorption of Osteocal important?

A: Proper absorption is critical to both the medicine's effectiveness and its safety profile. It is needed to ensure the medicine works as intended and, crucially, to prevent it from causing chelation (binding) that can lead to the reduced systemic exposure of other co-administered medications.


Q: Does Osteocal have an impact on kidney health?

A: Official information indicates that the medicine is contraindicated (should not be used) in patients who have severe renal impairment (severe kidney problems). It is also noted that the medicine's clearance may be altered in people with pre-existing kidney conditions, sometimes requiring monitoring.

How should Osteocal be stored and disposed of?

The official storage and disposal instructions for calcitonin-salmon nasal spray (related to Osteocal) strictly define pre- and in-use conditions.

Storage Requirements

Condition Requirement
Unopened Storage Refrigerate at 2 to 8C (36 to 46F); do not freeze.
In-Use Storage Store upright at room temperature (20 to 25C / 68 to 77F), away from heat and direct light.
Stability Limit Discard the opened bottle after 30 to 35 days, or after 30 doses, even if some medicine remains.

All medication must be kept out of the sight and reach of children.

Disposal

Disposal instructions mandate that unused or expired medicine should not be disposed of via wastewater or household trash. Users are directed to ask a pharmacist or healthcare professional for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Osteocal found in:

A-Z Index: